Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above
Condition: Respiratory Syncytial Virus Infections Interventions: Biological: RSVPreF3 OA Lot 1; Biological: RSVPreF3 OA Lot 2; Biological: RSVPreF3 OA Lot 3; Biological: RSVPreF3 OA Lot 4; Drug: Placebo Sponsor: GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials